...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>World Journal of Gastroenterology >Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?
【24h】

Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?

机译：5-氨基水杨酸盐​​在炎症性肠病中的适应症：证据是否完整？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Mesalazine is a safe drug, although adverse events may be seen in a minority of patients. This applies also to pregnant women and children. The role of mesalazine in combination therapy to improve efficacy and concomitant drug pharmacokinetics, or in chemoprevention against inflammatory bowel disease (IBD)-related colonic carcinoma has not yet been completely elucidated. Therapeutic success of mesalazine may be optimized by a combination of high dose and low frequency of dosage to improve compliance. Therefore, due to its superior safety profile and pharmacokinetic characteristics, mesalazine is preferable to sulphasalazine. This paper reviews the literature concerning mechanisms of action, indications and off-label use, pharmacokinetic properties and formulations, therapeutic efficacy, compliance, paediatric indications, chemoprevention, and safety issues and adverse event profile of mesalazine treatment versus sulphasalazine. It also highlights these controversies in order to clarify the potential benefits of mesalazines in IBD therapy and evidence for its use.
机译：美沙拉嗪是一种安全的药物，尽管少数患者可能会出现不良反应。这也适用于孕妇和儿童。美沙拉嗪在联合治疗中改善疗效和伴随药物药代动力学的作用，或在化学预防炎症性肠病（IBD）相关结肠癌中的作用尚未完全阐明。美沙拉嗪的治疗成功可以通过高剂量和低剂量频率的组合来优化，以改善依从性。因此，由于美沙拉嗪具有优越的安全性和药代动力学特性，因此它优于柳氮磺胺吡啶。本文综述了有关美沙拉嗪与柳氮磺吡啶治疗的作用机理，适应症和标签外使用，药代动力学特性和制剂，治疗功效，依从性，儿科适应症，化学预防以及安全性问题和不良事件概况的文献。它还阐明了这些争议，以阐明美沙拉嗪在IBD治疗中的潜在益处及其使用证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号